Navigation Links
Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
Date:2/23/2011

NEW YORK, Feb. 23, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs. Developed by Dr. Hideho Okada, Associate Professor of Neurological Surgery and his colleagues at Pitt, the vaccine demonstrated safety, tolerability, and anti-tumor activity as a single agent in a Phase I, National Institutes of Health-funded study conducted at Pitt in 22 participants with recurrent high-grade glioma.

According to Dr. Okada's research findings, published recently in the Journal of Clinical Oncology, the most common grade 1-2 adverse events (AEs) were injection site reactions and fatigue. There were no grade 3 or 4 AEs. The vaccine elicited immune responses in 81% of evaluable patients. A high rate of overall response and disease stabilization was observed in this heavily pre-treated population, including 46% (6/13) in glioblastoma (GBM), and 67% (6/9) in anaplastic glioma (AG). Notably, there was one durable complete response (CR) of greater than 12 months in a 1st salvage GBM patient, and one partial response (PR) of 7 months duration in a 2nd salvage GBM patient. In both cases, the vaccine induced tumor shrinkage as determined by MRI according to standard RECIST criteria. A survival improvement over historical data was also observed in both the recurrent GBM and AG populations. The vaccine and its derivatives are being developed by Stemline under the name SL-701 as both an "off-the-shelf" peptide vaccine and a dendritic cell (DC) vaccine.

Tom Cirrito, PhD, Director of Operations at Stemline noted, "We became interested in Pitt's vaccine because of its dual targeting of both tumor bulk and cancer stem cells. In addition, by virt
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
2. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
3. Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
4. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
5. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
8. Orexigen® Therapeutics Announces Corporate Realignment
9. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
10. Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
11. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Calif., July 22 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2008 after the market closes on Thursday, ... at 5:00 p.m. EDT,2:00 p.m. PDT, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... is bringing aboard Ashton S. Maaraba, a key Pharmacy, Pharmacy Services ... , ... (PRWEB) July 22, 2008 -- PharmaSmart International ... Ashton S. Maaraba, a key Pharmacy, Pharmacy Services & HBC industry ...
... U.S. Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley ... performed the first scanning tunneling spectroscopy of graphene flakes ... latest in a series of surprising insights into the ... carbon: an unexpected gap-like feature in the energy spectrum ...
Cached Biology Technology:CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2A phonon floodgate in monolayer carbon 2A phonon floodgate in monolayer carbon 3A phonon floodgate in monolayer carbon 4A phonon floodgate in monolayer carbon 5
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
(Date:7/9/2014)... receptor antagonists can alleviate the symptoms of ... cognitive dysfunction and effectively scavenge amyloid beta ... (Aβ) vaccines reduced and eliminated Aβ deposition ... model, and significantly improved behavioral and cognitive ... First Affiliated Hospital of China Medical University, ...
(Date:7/9/2014)... inhabitants of the sea: tiny haptophytes of the type ... eye, when they are in bloom in spring, they ... on satellite images. "Together with other phytoplankton, Emiliania ... global photosynthesis output," states Prof. Dr. Georg Pohnert of ... the greenhouse gas carbon dioxide CO2 is ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Short circuit in the food web 2
... tropical parasitic disease that can lead to life-threatening heart ... than previously thought, according to research from The University ... for four years now, and this year the number ... professor of integrative biology and philosophy at The University ...
... Cincinnati, OH, October 6, 2011 -- Directly advertising food ... providers, and the American Academy of Pediatrics and the ... impact of advertising on children,s healthy food choices. ... Journal of Pediatrics explores the relationship between ...
... can ever know about long-gone creatures is what they ... resurrect actual specimens and compare their features with their ... Toronto biologists helping to create a seed bank that ... allowing them to measure evolution caused by global change. ...
Cached Biology News:Chagas disease may be a threat in South Texas, says researcher 2Study suggests children's food choices are affected by direct advertising and parental influence 2Seed time-capsule will aid study of plant evolution amid environmental change 2